Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD133+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).

Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD133+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).

Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD1 33+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).

Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD1 33+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).

Abstract: The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.